Taiwan Biomaterial Co., Ltd.
TWO: 6649.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Derek Ma
- Employees
- 35
- Headquarters
- Zhubei, Taiwan
- IPO year
- 2017
- Market cap
- NT$1.7B
- Website
- https://www.twbm.com.tw
Loading 6649…
Loading profile data…Frequently asked questions about 6649
What does Taiwan Biomaterial Co., Ltd. (6649.TWO) do?
Taiwan Biomaterial Co., Ltd. engages in the development and sale of medical devices in Taiwan. The company provides Foamagen, a foamy dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and the nickel-titanium guidewire for guiding c...
Where does 6649.TWO trade?
Taiwan Biomaterial Co., Ltd. (6649.TWO) trades on the Taipei Exchange.
What sector is 6649.TWO in?
Taiwan Biomaterial Co., Ltd. (6649.TWO) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Taiwan Biomaterial Co., Ltd.?
Derek Ma is the chief executive officer of Taiwan Biomaterial Co., Ltd. (6649.TWO).
Where is Taiwan Biomaterial Co., Ltd. headquartered?
Taiwan Biomaterial Co., Ltd. is headquartered in Taiwan.
Does 6649.TWO pay a dividend?
Yes — Taiwan Biomaterial Co., Ltd. (6649.TWO) paid a trailing twelve-month dividend of TWD 1.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6649.TWO go public?
Taiwan Biomaterial Co., Ltd. (6649.TWO) completed its initial public offering in 2017.